Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Rubin

Showing results (651-660 of 717) with videos related to

Pageof 72
Sort By:
Cancer Research|July 23, 2003
The oncogene phosphatidylinositol 3'-kinase catalytic subunit alpha promotes angiogenesis via vascular endothelial growth factor in ovarian carcinomaLin Zhang, Nuo Yang, Dionyssios Katsaros, et al.
Gynecologic Oncology|July 15, 2011
Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group studyKian Behbakht, Michael W Sill, Kathleen M Darcy, et al.
American Journal of Obstetrics and Gynecology|July 1, 1990
Expression of P-glycoprotein in epithelial ovarian cancer: evaluation as a marker of multidrug resistanceS C Rubin, C L Finstad, W J Hoskins, et al.
Gynecologic Oncology|January 27, 1998
Cycles of dose-intensive chemotherapy with peripheral stem cell support in persistent or recurrent platinum-sensitive ovarian cancerM A Morgan, E A Stadtmauer, S M Luger, et al.
International Journal of Oncology|May 29, 2014
Differential expression of miRNAs in colon cancer between African and Caucasian Americans: implications for cancer racial health disparitiesEllen Li, Ping Ji, Nengtai Ouyang, et al.
Gynecologic Oncology|July 30, 2020
Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group studyKrishnansu S Tewari, Michael W Sill, Robert L Coleman, et al.
The New England Journal of Medicine|January 17, 2003
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancerLin Zhang, Jose R Conejo-Garcia, Dionyssios Katsaros, et al.
Gynecologic Oncology|August 9, 2011
Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: a gynecologic oncology group studyDon S Dizon, Michael W Sill, Natalie Gould, et al.
Gynecologic Oncology|January 1, 1993
High-resolution positron emission tomography of human ovarian cancer in nude rats using 124I-labeled monoclonal antibodiesS C Rubin, K J Kairemo, A L Brownell, et al.
Gynecologic Oncology|February 1, 2011
A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group studyMark A Morgan, Michael W Sill, Keiichi Fujiwara, et al.
Pageof 72

Showing results (651-660 of 717) with videos related to

Sort By:
Pageof 72
Cancer Research|July 23, 2003
The oncogene phosphatidylinositol 3'-kinase catalytic subunit alpha promotes angiogenesis via vascular endothelial growth factor in ovarian carcinomaLin Zhang, Nuo Yang, Dionyssios Katsaros, et al.
Gynecologic Oncology|July 15, 2011
Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group studyKian Behbakht, Michael W Sill, Kathleen M Darcy, et al.
American Journal of Obstetrics and Gynecology|July 1, 1990
Expression of P-glycoprotein in epithelial ovarian cancer: evaluation as a marker of multidrug resistanceS C Rubin, C L Finstad, W J Hoskins, et al.
Gynecologic Oncology|January 27, 1998
Cycles of dose-intensive chemotherapy with peripheral stem cell support in persistent or recurrent platinum-sensitive ovarian cancerM A Morgan, E A Stadtmauer, S M Luger, et al.
International Journal of Oncology|May 29, 2014
Differential expression of miRNAs in colon cancer between African and Caucasian Americans: implications for cancer racial health disparitiesEllen Li, Ping Ji, Nengtai Ouyang, et al.
Gynecologic Oncology|July 30, 2020
Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group studyKrishnansu S Tewari, Michael W Sill, Robert L Coleman, et al.
The New England Journal of Medicine|January 17, 2003
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancerLin Zhang, Jose R Conejo-Garcia, Dionyssios Katsaros, et al.
Gynecologic Oncology|August 9, 2011
Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: a gynecologic oncology group studyDon S Dizon, Michael W Sill, Natalie Gould, et al.
Gynecologic Oncology|January 1, 1993
High-resolution positron emission tomography of human ovarian cancer in nude rats using 124I-labeled monoclonal antibodiesS C Rubin, K J Kairemo, A L Brownell, et al.
Gynecologic Oncology|February 1, 2011
A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group studyMark A Morgan, Michael W Sill, Keiichi Fujiwara, et al.
Pageof 72